Phase I clinical trial of safety of L-serine for ALS patients

Abstract We performed a randomized, double-blind phase I clinical trial for six months on the effects of oral L-serine in patients with ALS. The protocol called for enrollment of patients with a diagnosis of probable or definite ALS, age 18–85 years, disease duration of less than three years and forced vital capacity (FVC) ≥ 60%. Patients were randomly assigned to four different oral twice-daily dose regimens (0.5, 2.5, 7.5, or 15 g/dose). Blood, urine and CSF samples, ALS Functional Rating Scale-Revised (ALSFRS-R) scores and forced vital capacity (FVC) were obtained throughout the trial. Disease progression was compared with matched historical placebo controls from five previous ALS therapeutic trials. Of 20 patients enrolled, one withdrew before receiving study drug and two withdrew with gastro-intestinal problems. Three patients died during the trial. L-serine was generally well tolerated by the patients and L-serine did not appear to accelerate functional decline of patients as measured by slope of their ALSFRS-R scores. Based on this small study, L-serine appears to be generally safe for patients with ALS.

[1]  Deborah C. Mash,et al.  Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain , 2016, Proceedings of the Royal Society B: Biological Sciences.

[2]  B. Bergman,et al.  Detection of BMAA in the human central nervous system , 2015, Neuroscience.

[3]  D. Mash,et al.  Cerebral uptake and protein incorporation of cyanobacterial toxin &bgr;-N-methylamino-L-alanine , 2013, Neuroreport.

[4]  P. Cox,et al.  The Non-Protein Amino Acid BMAA Is Misincorporated into Human Proteins in Place of l-Serine Causing Protein Misfolding and Aggregation , 2013, PloS one.

[5]  E. Stommel,et al.  Is exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and other neurodegenerative diseases? , 2013, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[6]  J. Cannon,et al.  The role of environmental exposures in neurodegeneration and neurodegenerative diseases. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  T. Hornemann,et al.  Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. , 2011, The Journal of clinical investigation.

[8]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[9]  W. Robberecht,et al.  Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease , 2011, The Lancet Neurology.

[10]  L. Klomp,et al.  L-serine synthesis in the central nervous system: a review on serine deficiency disorders. , 2010, Molecular genetics and metabolism.

[11]  Pamela A McCombe,et al.  Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[12]  D. Mash,et al.  Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease , 2009, Acta neurologica Scandinavica.

[13]  P. Cox,et al.  Co-occurrence of beta-N-methylamino-L-alanine, a neurotoxic amino acid with other cyanobacterial toxins in British waterbodies, 1990-2004. , 2008, Environmental microbiology.

[14]  H. Mitsumoto,et al.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial , 2007, The Lancet Neurology.

[15]  T. Koning.  Treatment with amino acids in serine deficiency disorders , 2006, Journal of Inherited Metabolic Disease.

[16]  P. Kaufmann,et al.  The ALSFRSr predicts survival time in an ALS clinic population , 2005, Neurology.

[17]  Paul Alan Cox,et al.  A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Paul Alan Cox,et al.  Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.